证券记录 · 已归档季度
APGE
Apogee Therapeutics, Inc. · Healthcare · Biotechnology
17被追踪持有人
-2Δ持有人
25.40M持有股份
$1.01B报告持仓市值
+0新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -10.5% ·
股份流向 -0.1% ·
净新建仓位 -11.8%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +12 | 31.80M | $4.18B | +21 | −9 |
| Q1 2026 | 96 | +7 | 41.18M | $3.45B | +13 | −6 |
| Q4 2025 | 88 | 0 | 38.24M | $2.89B | n/a | n/a |
| Q3 2025 | 17 | -2 | 25.40M | $1.01B | n/a | −2 |
| Q2 2025 | 16 | +1 | 22.08M | $959.13M | +1 | n/a |
| Q1 2025 | 12 | -1 | 10.37M | $387.41M | n/a | −1 |
| Q4 2024 | 13 | +4 | 9.16M | $415.03M | +4 | n/a |
| Q3 2024 | 8 | -5 | 7.45M | $437.40M | n/a | −5 |
| Q2 2024 | 13 | n/a | 6.20M | $244.16M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 6.92M | +0.1% | $274.79M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | Wellington Management ✦ | 4.72M | +24.1% | $187.67M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (被动) | 2.69M | +4.8% | $106.72M | 0.0% | ▲ Add | 2 | SEC ↗ ×11 |
| 4 | JPMorgan Chase ✦ | 2.28M | n/a | $90.40M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 5 | The Vanguard Group ✦ (被动) | 2.25M | +6.5% | $89.22M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 6 | State Street Global Advisors ✦ (被动) | 1.66M | +31.5% | $65.77M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 1.17M | +135.9% | $46.45M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Geode Capital Management ✦ (被动) | 892.20K | +14.0% | $35.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 750.53K | -1.4% | $29.82M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 599.62K | n/a | $23.82M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 464.96K | n/a | $18.47M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Millennium Management ✦ | 430.46K | +75.6% | $17.10M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 235.00K | -81.8% | $9.34M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Capital World Investors ✦ | 127.62K | -34.2% | $5.07M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 122.38K | +5.8% | $4.86M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 100.57K | -48.3% | $4.00M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Marshall Wace ✦ | 7.03K | -92.2% | $279,183 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Point72 Asset Management | $53.44M | 曾为 0.1% |
| Renaissance Technologies | $1.78M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 224 持有人, 77.95M 股份, $5.58B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
Sep 08
SC 13D/A: Venrock Healthcare Capital Partners…
Sep 03
SC 13D/A: Fairmount Funds Management LLC
Jul 08
SC 13G/A: T. Rowe Price Investment Management…
Jul 08
SC 13G/A: WELLINGTON MANAGEMENT GROUP LLP
Jul 08
SC 13G/A: FMR LLC
Jun 23
SC 13D/A: Fairmount Funds Management LLC
9.8% 占股份类别 · 查看 SEC 原始申报文件 ↗
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据